DelMar Pharmaceuticals Inc. (DMPI) presented promising data on the benefit of VAL-083, a groundbreaking anti-cancer drug, in combination with platinum-based chemotherapy in the treatment of non-small cell lung cancer (NSCLC). Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, the results are from a collaborative study on the potential of VAL-083 entitled, "Dianhydrogalactitol (VAL-083) enhances activity of platinum drugs in non-small cell lung cancer."
The study, conducted in conjunction with the MD Anderson Cancer Center, Shanghai Chest Hospital, and the BC Cancer Agency, support VAL-083 as a viable treatment option for NSCLC. Furthermore, the study supports the following potential therapeutic benefits of VAL-083 with platinum combination regimens:
● VAL-083 demonstrated cytotoxic activity in all tested NSCLC cell lines, including TKI-resistant cell lines.
● VAL-083 demonstrated super-additivity/synergy against NSCLC cell lines H460, A549 and H1975 when combined with either cisplatin or oxaliplatin, in vitro.
● VAL-083 is less dependent on p53 for its activity than both cisplatin and oxaliplatin, and appears to have a distinct mode of action in comparison to platinum-based chemotherapy.
● The combination of VAL-083 with cisplatin significantly decreased tumor growth and increased median survival time in a xenograft A549 in vivo model of NSCLC.
"We have recently shown that VAL-083's mechanism is distinct from platinum-based chemotherapy, the current standard of care for NSCLC, and is active against platinum and TKI-resistant NSCLC in both in vitro andin vivo models of lung cancer," said Jeffrey Bacha, president and CEO of DeMar. "The data presented today further demonstrate the non-overlapping mode of action between the platinum drugs and VAL-083 and the potential for treatment synergy in combination with therapeutic regimens."
Anti-Cancer Drug Continues to Show Promise
A biopharmaceutical company focused on the development and commercialization of new cancer therapies, DelMar Pharmaceuticals has announced a number of milestone achievements. VAL-083, the company’s first-in-class, small-molecule chemotherapeutic, is approved to treat chronic myelogenous leukemia lung cancer in China, and is currently undergoing clinical trials in the US. Furthermore, not only has company recently announced the completion of enrollment in a Phase II clinical trial of VAL-083 in refractory GBM, VAL-083 has also shown positive results in the treatment of pediatric brain cancer.
Non-small cell lung cancer is a disease where cancer cells form in the tissues of the lung. According to the American Cancer Society, 85% to 90% of lung cancers are non-small cell lung cancer. In the fight against this fatal disease, DelMar continues to make positive strides towards a cancer-free future. "These data are aligned with our strategy to leverage VAL-083's established clinical activity with modern biologic research to target specific, underserved markets where resistance to current standard-of-care is correlated with poor patient outcomes,” said Bacha. “This tactic establishes a personalized-medicine approach based on a potent and broadly-active chemotherapy to address significant unmet medical needs in the modern treatment of cancer.”
Equities.com had the opportunity to interview Jeffrey Bacha, President and CEO of DelMar Pharmaceuticals. The interview can be watchedhere. For more information about DelMar Pharmaceuticals, visit www.delmarpharma.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer